1. Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study. (12th June 2019) Authors: Ghia, P.; Pluta, A.; Wach, M.; Lysak, D.; Kozak, T.; Simkovic, M.; Kaplan, P.; Kraychok, I.; Illes, A.; De La Serna, J.; Dolan, S.; Campbell, P.; Musuraca, G.; Jacob, A.; Avery, E.J.; Lee, J.H.; Chen, T.; Liang, W.; Patel, P.; Jurczak, W. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 86 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies. (17th December 2017) Authors: Kralickova, P.; Kuhnova, J.; Soucek, O.; Vodarek, P.; Zak, P.; Simkovic, M.; Motyckova, M.; Smolej, L.; Mala, E.; Andrys, C.; Krejsek, J.; Thon, V. Other Names: Selvan Senthami R. Academic Editor. Journal: Journal of immunology research Issue: Volume 2017(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. IBRUTINIB DECREASES OBINUTUZUMAB‐INDUCED SECRETION OF CYTOKINES ASSOCIATED WITH INFUSION‐RELATED REACTIONS IN PATIENTS WITH CLL: ANALYSIS FROM THE ILLUMINATE STUDY. (12th June 2019) Authors: Greil, R.; Tedeschi, A.; Moreno, C.; Anz, B.; Larratt, L.; Simkovic, M.; Gill, D.; Gribben, J.G.; Flinn, I.W.; Wang, Z.; Cheung, L.W.; Nguyen, A.N.; Zhou, C.; Styles, L.; Demirkan, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 210 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. MAINTENANCE RITUXIMAB IMPROVES SURVIVAL IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: ANALYSIS OF THE CZECH LYMPHOMA STUDY GROUP. (June 2017) Authors: Obr, A.; Klener, P.; Belada, D.; Pytlik, R.; Simkovic, M.; Salek, D.; Mocikova, H.; Prochazka, V.; Janikova, A.; Markova, J.; Campr, V.; Kodet, R.; Trneny, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 205 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP. (23rd June 2022) Authors: Ghia, P.; Pluta, A.; Wach, M.; Lysak, D.; Simkovic, M.; Kriachok, I.; Illes, A.; de la Serna, J.; Dolan, S.; Campbell, P.; Musuraca, G.; Jacob, A.; Avery, E.; Lee, J. H.; Usenko, G.; Wang, M. H.; Yu, T.; Jurczak, W. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 566 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. R‐CHOP/R‐HDAC AND RITUXIMAB MAINTENANCE RESULTS IN HIGH COMPLETE REMISSION RATE, MINIMAL RESIDUAL DISEASE NEGATIVITY, AND EXCELLENT SURVIVAL IN ELDERLY MCL PATIENTS. (June 2017) Authors: Klener, P.; Fronkova, E.; Belada, D.; Forsterova, K.; Pytlik, R.; Kalinova, M.; Simkovic, M.; Salek, D.; Mocikova, H.; Prochazka, V.; Blahovcová, P.; Janikova, A.; Markova, J.; Obr, A.; Berkova, A.; Vaskova, M.; Mejstrikova, E.; Campr, V.; Kubinyi, J.; Jaksa, R. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 204 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗